Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Molecular Basis of Disease(Sem 4) > Overview of Genomic technologies in Clinical diagnosis > Flashcards

Overview of Genomic technologies in Clinical diagnosis Flashcards

1
Q

What are some different genomic technologies ?

A
  • PCR
  • Fragment analysis
  • Sanger Sequencing
  • Fluorescence in situ hybridisation (FISH)
  • Array - comparative genomic hybridization (Array CGH)
  • Multiplex ligation-dependent probe amplification (MLPA)
  • Next-Generation sequencing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe PCR

A
  • PCR is used to amplify a specific region of DNA
  • Design specific primers which are oligonucleotide sequences =complimentary to amplicon
  • Primers flank the region you want to amplify.
  • Each cycle doubles the amount of DNA copies of your target sequence
  • Amplify enough DNA molecules = have sufficient material for downstream applications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the three steps of PCR -

A

Denaturation -High temperature permits separation of DNA strands

Annealing- Cooler temperature allows primer to attach to ends of target sequence

Extension-Temperature allowing thermostable polymerase to add nucleotides at the 3’ end of primers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is Capillary electrophoresis

A

PCR based assay
Following PCR we carry out capillary electrophoresis
(This is a technique which separates ions based on electrophoretic mobility )
-We size the PCR product
-This can be used to detect repeat expansions or small size changes (up to a few hundred bp)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a repeat expansion disorder ?

A

Genetic diseases that are caused by expansions in DNA repeats.

Example- Huntington’s disease (severe neurodegenerative disorder )

Cause -CAG repeat expansion in the HTT gene

Normal - less than 27 copies
Intermediate-27-35
Pathogenic-35 copies

Expanded protein is toxic and accumulates in neurons causing cell death

Can be diagnosed using capillary electrophoresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe Sanger sequencing

A
  • Each of the 4 DNA nucleotides has a different dye so we can determine the nucleotide sequence.
  • Up to 800bp of sequence per reaction
  • Good for sequencing single exons of genes
  • Slow, low-throughput and costly to perform for large numbers of samples
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What can sanger sequencing be used for?

A

We can identify single nucleotide polymorphisms (SNPs), or mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe FISH (Fluorescent in situ hybridisation)

A

It is used to detect (Microscopic) large chromosomal abnormalities

Cells from patients spread during metaphase

Can look for:
•Extra chromosomes
•Large deleted segments
•Translocations(chunks of chromosomes moving from one place to another)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does FISH work?

A
  1. Design Fluorescent probe to chromosomal region of interest
  2. Denature probe and target DNA
  3. Mix probe and target DNA (hybridisation)
  4. Probe binds to target
  5. Target fluoresces or lights up so we can see our target
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What type of observations can we make using FISH

Outline two ways FISH can be used

A

Special Karyotyping

-pairs of chromosomes are manipulated to have distinctive colours.
makes it easier to detect chromosomal abnormalities
(Trisomy 21)-Three copies of 21 -Down syndrome

Target specific
-Probe for specific chromosomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is Array CGH (comparative genomic hybridisation )

A

Used to detect sub-microscopic chromosomal abnormalities .

Patients DNA labelled Green
Control DNA labelled Red

Can see patient sample whether it has net loss/gain
Increased green signal will show a gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe MLPA

A

Multiplex ligation-dependent probe amplification

  • Variation of PCR that permits amplification of multiple targets
  • Probe= two oligonucleotides -recognise adjacent target sits on DNA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What can MLPA be used to detect?

A

Use:
-To detect abnormal copy numbers at specific chromosomal locations

-Can detect sub-microscopic gene deletions/partial gene deletions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How does MLPA work?

A

Three step process

  1. Hybridisation
    - Two probes are hybridised (forward/reverse primer)
  2. Ligation
    - Join together the two probes

3.Amplification
PCR amplification of the two probes to generate an amplified library

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How can we analyse following MLPA?

A

Using capillary electrophoresis
(fragment analysis)

-Used to determine ploidy(how many chromosome copies)-specific locations

-Signal strength of the probes is compared to those obtained from reference DNA sample
(contains two copies of the chromosome )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe Next Gen sequencing

A

Where we only sequence known disease genes relevant to the phenotype

17
Q

Describe Exome Sequencing

A

One of the common techniques of Next Gen sequencing

Only interested in the protein coding exons
(1-2% of the genome )

  • Pathogenic mutations -80% are protein coding
  • This is more efficient
18
Q

How do we actually perform whole exome sequencing?

A

-Target enrichment
This is capturing target regions of interest with “baits”
-There is the potential to capture several Mb of genomic regions

-We incubate our RNA bases

19
Q

What is target enrichment ?

A

cost-effective and efficient method for researchers to capture specific regions of interest after library preparation for NGS

20
Q

What takes place once we create our DNA library

Whole exome sequencing ?

A
  1. Incubate our DNA library with RNA “baits “
  2. perform hybridisation and the exons are “baited”
  3. Purification column using magnetic beads (Streptavidin) which recognise biotin on RNA baits
  4. Capture the exons
  5. Wash away any unbound fragments,introns
  6. Gives us a enriched library
21
Q

What has replaced SANGER sequencing?

A

Next generation sequencing

22
Q

Why will not all testing be suitable for Whole genome sequencing ?

A
  1. Panels/single gene tests may still be more suitable for some diseases, e.g. cystic fibrosis
  2. Capillary-based methods: Repeat expansions, MLPA, family mutation confirmation Sanger sequencing
  3. Array-CGH: large sized chromosomal aberrations
23
Q

What are some challenges with Exome and Genome Sequencing ?

A

Result interpretation :

  • 20,000 genetic variants identified per coding genes ‘exome’
  • 3 million variants in a whole human genome

Ethical considerations:

  • Modified patient consent process
  • Data analysis pathways – inspect relevant genes first
  • Strategy for reporting ‘incidental’ findings

Infrastructure and training (particularly IT and clinical scientists)

24
Q

Describe the 100,000 genomes project

A
  • Whole genome sequencing
  • Direct benefit of whole genome sequencing and genetics to patients
  • New scientific discoveries and medical insights
  • Personalised medicine
25
Q

How is the 100,000s genome project carried out

A
  • England wide collection of samples
  • Rare disease -Index cases +families -inheritance patterns
  • Cancer treatments (Germline (blood) and tumour samples )
26
Q

Describe the clinical interpretation of the genome project

A 
Classifications of the mutations :
They are divided into three tiers-
Tier 1 variants
-Known pathogenic
-Protein truncating
Tier 2 variants 
-Protein altering (missense)
-Intronic (splice site)
Tier 3 variants
-Loss-of-function variants in genes not on the disease gene panel
27
Q

What is clinical validity ?

A

How well the tests predict the phenotype

28
Q

What is clinical utility?

A

How the tests adds to the management of the patient

29
Q

What type of tests do the NHS Diagnostic laboratory do ?

A
  • Diagnostic
  • Predictive
  • Carrier (recessive)
  • Diagnostic
  • Informed consent
30
Q

What are diagnostic test outcomes ?

A
  • Pathogenic mutation
  • Normal variation( polymorphism )
  • Novel variant (Investigations to establish clinical significcace]
31
Q

How do we establish if a mutation is pathogenic ?

A

-Mode of inheritance
-Genetic databases of published and unpublished
-Nonsense , frameshifts, splice site
-Missense/intronic mutation
(In-Silico tools for missense and splicing mutations)

32
Q

How do we interpret results ?

A
  • We do not report polymorphisms

- Request further samples from family

33
Q

What is MFN2?

A

Mitofusin 2 causes Charcot-Marie-Tooth disease (CMT2)

  • Degeneration of the long nerves in the legs and arms leading to muscle wasting and sensory defects
  • Onset-childhood
  • Autosomal dominant +Autosomal recessive

Molecular Basis of Disease(Sem 4) (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions